An investigation for current long-term investors in NYSE:BI shares over potential wrongdoing at Bio-Rad Laboratories was announced and NYSE:BIO stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 09/08/2015 -- An investigation for long-term investors in NYSE:BIO shares concerning potential wrongdoing by certain Bio-Rad Laboratories directors. that caused damages to NYSE:BIO stockholders
Investors who purchased shares of Bio-Rad Laboratories, Inc. (NYSE:BIO), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation or call 858-779-1554.
The investigation by a law firm focuses on whether certain statements by regarding Bio-Rad Laboratories' business, its prospects and its operations were materially false and misleading at the time they were made.
On November 4, 2014, Bio-Rad Laboratories, Inc. reported its third quarter 2014 financial results. Among other things, Bio-Rad Laboratories, Inc. said that in May 2010 it disclosed to the U.S. Department of Justice ("DOJ") and the Securities and Exchange Commission ("SEC") certain likely or potential violations of the United States Foreign Corrupt Practices Act ("FCPA") and that effective November 3, 2014, it entered into a non-prosecution agreement with the DOJ and consented to the entry of an Order by the SEC (SEC Order), which actions resolve both the DOJ and the SEC investigations. Bio-Rad Laboratories, Inc. said that the non-prosecution agreement with the DOJ concerns violations of the FCPA's books and records and internal control provisions related to Russia during 2005-2010. And that pursuant to the non-prosecution agreement Bio-Rad Laboratories agreed to pay a penalty of $14.4 million and to certain compliance, reporting and cooperation obligations, and the DOJ agreed that it will not criminally prosecute Bio-Rad Laboratories for any crimes related to conduct disclosed to the DOJ, provided that Bio-Rad Laboratories performs its obligations under the non-prosecution agreement for two years. Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) declined on November 5, 2014, to as low as $102.71 per share.
Those who purchased shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego